Investors
Partners
Our Pipeline

We are building a pipeline of compelling investigational therapies targeting indications for which we believe gene therapy can have the greatest impact in patients with rare genetic diseases.

Our Products

Hunterase®, (iduronidase-2-sulfatase) is a recombinant human Enzyme Replacement Therapy (ERT).

Livmarli is an oral, minimally absorbed, reversible inhibitor of the ileal bile acid transporter (IBAT).

NERLYNX® (Neratinlib) is a potent irreversible tyrosine kinase inhibitor, that inhibits tumor growth and metastasis through blocking pan-HER family proteins (HER1, HER2, and HER4) and downstream signal transduction.

Corporate Culture & Career

To be a global biopharmaceutical company delivering life-changing therapeutics built upon a foundation in China

Contact Us
Beijing
Beijing
Room1501, 15/F(16), No. 10, Futong East Street, Chaoyang District, Beijing.
Tel: 010 6478 0016
Fax: 010 6478 0019
Adverse Events Reporting: PV@canbridgepharma.com
Shanghai
Shanghai
Suite 708, Huawen International Mansion, No.999, West Zhongshan Road, Changning District, Shanghai
Tel: 021 52956319
Fax: 021 52665300
Adverse Events Reporting: PV@canbridgepharma.com
Hong Kong
Hong Kong
Rm B01, 20/F, CITIC Tower, 1 Tim Mei Avenue, Admiralty, Hong Kong
Adverse Events Reporting: PV@canbridgepharma.com
Taiwan
Taiwan
Room209, 2F, No. 141, Sec. 1, Keelung Rd., Xinyi Dist., Taipei, Taiwan
Adverse Events Reporting: PV@canbridgepharma.com
Burlington
Burlington
4 Burlington Woods Drive, Burlington, MA 01803, USA